Trial Parameters
Condition GERD in Children
Sponsor Duke University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 2 Years
Max Age 18 Years
Start Date 2024-10-23
Completion 2026-06-30
All Conditions
Interventions
Discontinuation of GERD therapy
Brief Summary
The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.
Eligibility Criteria
Inclusion Criteria: * Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations. * Signed consent Exclusion Criteria: * Declining to participate in the study or sign consent * History of severe GERD per gastroenterology diagnosis and documentation * GSAS score \>80